All Trials

A Phase 2 Study of DRP-104, a Glutamine Antagonist, in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: Enrolling adults with advanced/metastatic or unresectable NSCLC harboring NFE2L2 or KEAP1 alterations who have RECIST-measurable disease and have progressed after prior platinum-based chemotherapy and anti–PD-1/PD-L1 therapy (ECOG 0–1; stable treated brain metastases allowed). Patients receive single-agent DRP-104 (sirpiglenastat) subcutaneously twice weekly in continuous 21-day cycles; DRP-104 is a tumor-targeted prodrug of DON, a broad glutamine antagonist that irreversibly inhibits multiple glutamine-utilizing enzymes.

ClinicalTrials.gov ID: NCT07249372

FRAmework-01: A Two-Part Phase 3 Study of LY4170156 Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and LY4170156 Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer.

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: Adults with recurrent high-grade serous ovarian/primary peritoneal/fallopian tube cancer (ECOG 0–1, measurable disease) are enrolled in two cohorts: platinum-resistant relapse ≤6 months after platinum after 1–3 prior cytotoxic lines (Part A) or platinum-sensitive relapse >6 months after first-line platinum with 1–2 prior lines and prior PARP inhibitor exposure per label (Part B); prior topo I–payload ADCs are excluded. Part A randomizes IV LY4170156 (FRα-targeted antibody–drug conjugate delivering the topoisomerase I inhibitor exatecan) vs single-agent chemo (paclitaxel/topotecan/gemcitabine/PLD) or mirvetuximab soravtansine, and Part B randomizes LY4170156 + bevacizumab vs platinum doublet chemotherapy + bevacizumab.

ClinicalTrials.gov ID: NCT07213804

A Phase 1b Study of Pasritamig (JNJ-78278343), a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With JNJ-86974680, an A2a Receptor (A2aR) Antagonist, for Prostate Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling adults with metastatic castration-resistant prostate adenocarcinoma with bone and/or nodal metastases and no clear visceral metastases (on ongoing castration; PSA ≥2 ng/mL; ECOG 0–1). Participants receive IV pasritamig (JNJ-78278343), a KLK2×CD3 bispecific T-cell–redirecting antibody to drive T-cell–mediated tumor lysis, in combination with JNJ-86974680, an adenosine A2A receptor antagonist intended to relieve adenosine-mediated T-cell immunosuppression.

ClinicalTrials.gov ID: NCT07319871

A Phase 1, Multicenter Trial Evaluating the Safety, Tolerability, and Efficacy of Valemetostat (DS-3201) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: For adult men with metastatic castration-resistant prostate adenocarcinoma (including neuroendocrine differentiation but not pure small cell) progressing on ongoing androgen deprivation therapy and previously treated with at least one androgen receptor pathway inhibitor (ECOG 0–1, PSA ≥2). Patients receive oral valemetostat (investigational dual EZH1/EZH2/PRC2 inhibitor that reduces H3K27me3 to reverse transcriptional repression) in combination with oral darolutamide, with continued background ADT, in dose-escalation/expansion to assess safety and preliminary antitumor activity.

ClinicalTrials.gov ID: NCT07244341

TulmiSTAR-02: A Two-part Phase I Dose Escalation Study of Tulmimetostat (DZR123) in Combination With Darolutamide or Abiraterone Followed by Open-label, Randomized, Phase II Dose Expansion Study to Assess the Safety and Efficacy of Tulmimetostat in Combination With Darolutamide Versus Darolutamide Alone in Patients With Metastatic Hormone-sensitive Prostate Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: For men with de novo or recurrent metastatic hormone-sensitive prostate cancer on ongoing ADT (castrate testosterone; ECOG 0–2), including those with limited prior taxane and ≤6 months prior ARPI exposure (no ongoing darolutamide) and at least one metastatic lesion. Evaluates adding tulmimetostat (DZR123), an oral dual EZH1/EZH2 (PRC2) inhibitor, to darolutamide (and in dose-escalation also with abiraterone/prednisone) versus darolutamide alone while continuing ADT.

ClinicalTrials.gov ID: NCT07190300

Pilot Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP) and PD-1 Blockade, With Targeted Ablation of Resistant Lesions, in Patients With Non-Castrate Recurrent Oligometastatic Prostate Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with prostate adenocarcinoma post-prostatectomy (± prior adjuvant/salvage RT ≥3 months) who have biochemical recurrence with non-castrate testosterone and oligometastatic disease (<3 lesions on conventional imaging and PSMA PET/CT; ECOG 0–1) receive intradermal pTVG-HP/MVI-816, a plasmid DNA vaccine encoding prostatic acid phosphatase (PAP) to elicit PAP-specific T-cell responses, combined with nivolumab (PD-1 blockade). Lesions deemed treatment-resistant during therapy are ablated with targeted radiation.

ClinicalTrials.gov ID: NCT07090148

Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: For children, adolescents, and young adults (≤21 years) with relapsed/refractory B7-H3 (CD276)–positive sarcomas (including osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, and other soft-tissue sarcomas) who have at least one lesion amenable to hypofractionated radiation. Treatment is hypofractionated radiation priming to ≥1 tumor site with fludarabine/cyclophosphamide lymphodepletion followed by IV infusion of autologous B7-H3–directed CAR T cells (genetically engineered T cells targeting the tumor antigen B7-H3).

ClinicalTrials.gov ID: NCT07222735

Phase I Study With Expansion Cohort of Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults (≥18) with metastatic or unresectable soft tissue sarcoma (RECIST-measurable, ECOG 0–1) who have progressed after 1–3 prior metastatic lines (ASPS allowed without prior refractoriness) and have had no prior PD-1/PD-L1/CTLA-4 therapy or zanzalintinib/cabozantinib. Treatment is oral zanzalintinib (XL092), a multikinase TKI targeting VEGFR2/MET/TAM (TYRO3/AXL/MER), combined with nivolumab (PD-1 inhibitor) plus ipilimumab (CTLA-4 inhibitor) induction, followed by maintenance nivolumab with ongoing daily zanzalintinib.

ClinicalTrials.gov ID: NCT06968988

A Multicenter, Open-label, Interventional Phase I Trial to Determine the Dose and Evaluate the Pharmacokinetics (PK) and Safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as Monotherapy or Following Standard of Care (SoC) for the Treatment of Somatostatin Receptor-positive Tumors in the Pediatric Population (KinLET).

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling children and adolescents aged 2 to <18 years with relapsed/progressive/refractory somatostatin receptor–positive malignancies (e.g., neuroendocrine tumors, CNS tumors, lymphoma, other solid tumors) after ≥1 prior therapy, requiring SSTR expression by IHC and uptake on SSTR PET/SPECT greater than liver. Patients receive IV lutetium Lu 177 edotreotide (177Lu-DOTATOC) peptide receptor radionuclide therapy—a radiolabeled somatostatin analog targeting SSTR2 to deliver localized beta radiation—every 8 weeks for up to 6 doses (with amino acids for renal protection), either as monotherapy or after standard-of-care therapy.

ClinicalTrials.gov ID: NCT06441331

Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: For adults with relapsed small cell lung cancer progressing after at least one prior platinum-based regimen (prior anti–PD-(L)1 allowed; ECOG 0–2; measurable disease; prior irinotecan allowed if not stopped for intolerance), this single-arm study evaluates irinotecan (days 1 and 8 every 21 days) combined with cirtuvivint (SM08502), an oral CDC2-like kinase (CLK) and DYRK inhibitor that modulates alternative pre-mRNA splicing (with downstream transcriptional effects including reduced Wnt-pathway gene expression). The trial dose-escalates to a recommended dose then expands to assess objective response rate, with PFS and OS as secondary outcomes.

ClinicalTrials.gov ID: NCT07155200